Four manufacturers have signed sub-licence agreements with the Medicines Patent Pool (MPP) to produce generic versions of Nilotinib for chronic myeloid leukaemia. These manufacturers are:

• Strides Pharma Science - a global pharmaceutical company with a focus on developing and manufacturing generics
• Aurobindo Pharma - a leading Indian multinational pharmaceutical company with a focus on developing, manufacturing and marketing medications
• Emcure Pharmaceuticals - another Indian-based company that has a portfolio of over 1000 products across different therapeutic areas
• MSN Laboratories - an Indian-based company that researches, develops and manufactures active pharmaceutical ingredients (APIs) and formulations

By allowing more manufacturers to produce generic versions of the drug, it is hoped that the cost of treatment for chronic myeloid leukaemia will become more affordable, especially in lower-income countries.